344 related articles for article (PubMed ID: 36046821)
21. Hypoxia, but Not Normoxia, Reduces Effects of Resveratrol on Cisplatin Treatment in A2780 Ovarian Cancer Cells: A Challenge for Resveratrol Use in Anticancer Adjuvant Cisplatin Therapy.
Synowiec A; Brodaczewska K; Wcisło G; Majewska A; Borkowska A; Filipiak-Duliban A; Gawrylak A; Wilkus K; Piwocka K; Kominek A; Waś H; Lewicki S; Siewiera J; Szczylik C; Szenajch J; Kubiak JZ; Kieda C
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982788
[TBL] [Abstract][Full Text] [Related]
22. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.
Ma L; Lai D; Liu T; Cheng W; Guo L
Acta Biochim Biophys Sin (Shanghai); 2010 Sep; 42(9):593-602. PubMed ID: 20705681
[TBL] [Abstract][Full Text] [Related]
23. Withaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells.
Kakar SS; Ratajczak MZ; Powell KS; Moghadamfalahi M; Miller DM; Batra SK; Singh SK
PLoS One; 2014; 9(9):e107596. PubMed ID: 25264898
[TBL] [Abstract][Full Text] [Related]
24. Downregulated lincRNA HOTAIR expression in ovarian cancer stem cells decreases its tumorgeniesis and metastasis by inhibiting epithelial-mesenchymal transition.
Wang J; Chen D; He X; Zhang Y; Shi F; Wu D; Chen J; Zhang Y; Zhao F; Dou J
Cancer Cell Int; 2015; 15():24. PubMed ID: 25792974
[TBL] [Abstract][Full Text] [Related]
25. Modulating the Siah2-PHD3-HIF1α axis and/or autophagy potentially retard colon cancer proliferation possibly, due to the damping of colon cancer stem cells.
Zakaria S; Elsebaey S; Allam S; El-Sisi A
Biomed Pharmacother; 2022 Oct; 154():113562. PubMed ID: 35994813
[TBL] [Abstract][Full Text] [Related]
26. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
Zhang X; Qi Z; Yin H; Yang G
Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Wang Z; Shi Q; Wang Z; Gu Y; Shen Y; Sun M; Deng M; Zhang H; Fang J; Zhang S; Xie F
Pathol Res Pract; 2011 Aug; 207(8):505-13. PubMed ID: 21802218
[TBL] [Abstract][Full Text] [Related]
28. Blocking heme oxygenase-1 by zinc protoporphyrin reduces tumor hypoxia-mediated VEGF release and inhibits tumor angiogenesis as a potential therapeutic agent against colorectal cancer.
Cheng CC; Guan SS; Yang HJ; Chang CC; Luo TY; Chang J; Ho AS
J Biomed Sci; 2016 Jan; 23():18. PubMed ID: 26822586
[TBL] [Abstract][Full Text] [Related]
29. [Relationship of hypoxia-inducible factor-1alpha expression and vascular endothelial growth factor in SKOV-3 ovarian cancer model].
Jiang HY; Feng YJ
Zhonghua Fu Chan Ke Za Zhi; 2004 Nov; 39(11):767-70. PubMed ID: 15634505
[TBL] [Abstract][Full Text] [Related]
30. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
[TBL] [Abstract][Full Text] [Related]
31. [Effect of Brucea javanica fruit oil emulsion combined cisplatin on the growth inhibition of transplanted tumor in human ovarian cancer SKOV3 nude mice: an experimental study].
Zhao Nan ; Li YH; Wu XK; Wang GY; Cai DY; Han FJ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jan; 35(1):57-62. PubMed ID: 25790676
[TBL] [Abstract][Full Text] [Related]
32. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
33. Adrenomedullin promotes angiogenesis in epithelial ovarian cancer through upregulating hypoxia-inducible factor-1α and vascular endothelial growth factor.
Zhang Y; Xu Y; Ma J; Pang X; Dong M
Sci Rep; 2017 Jan; 7():40524. PubMed ID: 28091613
[TBL] [Abstract][Full Text] [Related]
34. Scutellaria baicalensis targets the hypoxia-inducible factor-1α and enhances cisplatin efficacy in ovarian cancer.
Hussain I; Waheed S; Ahmad KA; Pirog JE; Syed V
J Cell Biochem; 2018 Sep; 119(9):7515-7524. PubMed ID: 29797601
[TBL] [Abstract][Full Text] [Related]
35. Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis.
Wang J; Li G; Wang Y; Tang S; Sun X; Feng X; Li Y; Bao G; Li P; Mao X; Wang M; Liu P
Oncotarget; 2015 Dec; 6(42):44579-92. PubMed ID: 26625311
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer.
Jiang H; Feng Y
Int J Gynecol Cancer; 2006; 16 Suppl 1():405-12. PubMed ID: 16515634
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Angiogenesis Process after Metformin and LY294002 Treatment in Mammary Tumor.
Moschetta MG; Leonel C; Maschio-Signorini LB; Borin TF; Gelaleti GB; Jardim-Perassi BV; Ferreira LC; Sonehara NM; Carvalho LGS; Hellmén E; de Campos Zuccari DAP
Anticancer Agents Med Chem; 2019; 19(5):655-666. PubMed ID: 30569877
[TBL] [Abstract][Full Text] [Related]
39. Systemic mesenchymal stem cells reduce growth rate of cisplatin-resistant ovarian cancer.
Zhu P; Chen M; Wang L; Ning Y; Liang J; Zhang H; Xu C; Chen S; Yao L
Int J Clin Exp Pathol; 2013; 6(11):2506-14. PubMed ID: 24228113
[TBL] [Abstract][Full Text] [Related]
40. Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial.
Karihtala P; Mäenpää J; Turpeenniemi-Hujanen T; Puistola U
Anticancer Res; 2010 Mar; 30(3):1001-6. PubMed ID: 20393027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
